How We Prevail

We cannot prevail if we do not reflect. As we drive the progress of cancer care, we acknowledge the events and accomplishments of the last year. The Annual Report gives us the opportunity to formalize our reflections and to share these successes with you.

From the major headlines to clinical advances, research breakthroughs, and fundraising milestones, we recap our work here with highlights of fiscal year 2018 (July 1, 2017 through June 30, 2018). We celebrate our achievements, and in doing so, inspire our supporters—and each other—to build on the progress we have made.

True to our century-long legacy, we distinguished ourselves through proof of performance, expansion of facilities and services, recruitment of new talent, and partnerships with key figures in our community. Consistently, our mission of comprehensive cancer care emphasizes the importance of both the clinic and the laboratory in pursuing the newest treatments and increasing our understanding of cancer.

In the clinical realm, we are seeing exciting results in patients with rare, difficult-to-diagnose neuroendocrine tumors because of a new, personalized treatment that finds and destroys the tumor cells from within. For eligible patients with leukemia and lymphoma, we began using an intensive form of immunotherapy to extract and alter T-cells from a patient’s blood, then re-infuse the modified cells into the patient to target and eliminate cancer cells. Finally, we became one of a select few institutions to perform a more complete removal of early stage bladder cancer using a revolutionary new approach. It significantly reduces the chances of recurrence by treating the cancer with greater accuracy.

Within our research enterprise, we are helping patients for whom the promise of immunotherapy has not worked—with significant support from Stand Up To Cancer. Specifically, this research focuses on whether a particular drug can reverse the resistance of some bladder cancers to treatment because of DNA silencing in the body. In addition, our pancreatic cancer research program is building considerable strength after the receipt of a transformational gift in 2017. We have recruited key members to our research team and earned multiple additional grants to fund important work, including development of a database that will expedite and improve information sharing for multidisciplinary collaborative grants and projects.

Support is critical to funding our efforts. This year marked the continued growth of our signature gala event, during which we received a notable surprise bid from one of our own faculty members; increased interest and involvement by young professionals as a growing subset of our donor base; and a special anniversary for an important circle of friends.

As another year gets underway, we honor this work while looking ahead. What are the discoveries that we will uncover next? What achievements will we realize? I invite you to join us, support us, and encourage us as we pursue what is yet to come.

Richard I. Fisher, MD
PRESIDENT AND CEO AT FOX CHASE
“True to our century-long legacy, we distinguished ourselves through proof of performance, expansion of facilities and services, recruitment of new talent, and partnerships with key figures in our community.”
— Richard I. Fisher, MD, president and CEO
COMMUNITY

- OPENING OF EAST NORRITON CAMPUS
- LOCAL LEADERS SUPPORTFOX CHASE
- UNITE FOR HER
- PATIENT-TO-PATIENT NETWORK
- NURSING DEPARTMENT EARNSMAGNET DESIGNATION
Opening of East Norriton Campus

On May 8, Fox Chase Cancer Center opened a new outpatient facility in East Norriton, Pennsylvania. Located on the campus of Suburban Community Hospital, Fox Chase Cancer Center East Norriton – Hospital Outpatient Center offers access to Fox Chase’s specialized team of providers in a suburban setting, allowing patients to be treated closer to home.

The location features two full floors of clinical space, which includes a linear accelerator for radiation treatments, flexible clinic space with seven exam rooms, an infusion center with seven infusion chairs, and a healing garden.

From the beginning, Fox Chase East Norriton offered hematology and medical oncology services, including chemotherapy and immunotherapy, for most types of cancer and benign blood conditions, radiation oncology, and surgical consultations. It has since expanded to offer genetic counseling and testing, as well as plastic and reconstructive surgical consultations to address physical changes that can result from cancer treatment. Through genetic counseling and testing, patients can learn about genetic factors that may increase the risk of developing cancer, and get help with long-term plans to reduce their risk.

Patients at Fox Chase East Norriton also have access to nurse navigation services, clinical trials, and other support services offered at the Fox Chase Main Campus. Services will continue to expand at Fox Chase East Norriton to provide a convenient option in the suburbs.

Local Leaders Support Fox Chase

Fox Chase deepened its ongoing relationships with several state and federal leaders in 2018. As a major employer and healthcare provider within Pennsylvania’s 13th Congressional District, Fox Chase has a dramatic impact on this region. Congressman Brendan F. Boyle visited the Center over the summer, and has been a partner in supporting the Center’s clinical, research, and outreach efforts in the community.

In February, State Senator Christine Tartaglione and State Representative Kevin Boyle presented Fox Chase with a check for $500,000 from the Redevelopment Assistance Capital Program of the Commonwealth of Pennsylvania. This funding will support a planned expansion of the infusion room.

The Office of Community Outreach is Fox Chase’s bridge to the community, reaching more than 13,000 people in the region in 2018. Outreach efforts included multiple health and wellness events. Numerous area leaders hosted or jointly participated, including State Representative Matt Bradford at the Meadowbrook Senior Living Community, State Representative Steve McCarter for the Senior Expo in Elkins Park, and State Representative Christopher Rabb for the Grown Folks Festival in Philadelphia. Fox Chase was one of more than 40 vendors at the Fox Chase National Night Out event hosted by State Representative Boyle at the Fox Chase Elementary School.

Additionally, the Fox Chase Mobile Screening Unit, in partnership with Flyers Charities, provided breast cancer screening for the constituents of Representatives Boyle, Mary Jo Daly, John Sabatina, and Kate Harper.
Unite for Her
The non-profit organization Unite for Her has partnered with Fox Chase to bring a wide range of wellness services to breast cancer patients. They provide nutrition counseling, yoga, meditation, exercise therapy, acupuncture, massage, reiki, and professional counseling all free of charge. Unite for Her held several wellness days at Fox Chase throughout the year, where patients learned more about services that can complement their medical care. Patients were given a passport, allowing them to utilize the services from area vendors and providers throughout the year.

Patient-To-Patient Network
In 2018, Fox Chase launched the Patient-to-Patient Network, a phone-based support program for cancer patients. The program connects patients beginning their cancer journey
The Department of Nursing successfully achieved its fifth consecutive Magnet® designation for nursing excellence from the American Nurses Credentialing Center. Fox Chase has held Magnet status continuously since 2000, and is one of only nine hospitals globally to earn it five times.

The Magnet Recognition Program is regarded as the nation’s highest form of recognition for excellence in nursing. Applicants are scored on patient satisfaction, nurse satisfaction, adherence to standards for improving the quality of patient care, inter-professional collaboration, leadership of the chief nurse executive in supporting professional practice, and continued competence of nursing personnel. •
with survivors who have had the same cancer, undergone similar treatments, or faced some of the same issues.

Patients have long expressed a desire for this type of one-on-one support, and survivors are often looking for a way to give back. Understanding the benefit of shared experience, Fox Chase responded by creating the Patient-to-Patient Network, and the program began helping people immediately.

“Knowing what to expect from survivors greatly reduced my anxiety about starting treatment and made me more confident in my decision to seek treatment at Fox Chase,” said one recently matched patient.

Newly diagnosed patients are carefully matched with cancer survivors who are specially trained. Patient-to-Patient Network volunteers help address patient concerns, share personal journeys, and provide empathetic support and encouragement. To date, the program has more than 100 volunteers representing a wide range of cancers, and is still recruiting. The program is coordinated through the Philip E. and Naomi P. Lippincott Resource and Education Center, a patient and family learning center designed to provide information about cancer risk, prevention, screening, and treatment options such as clinical trials.

“The incredible care the nursing staff provided to me had a profound effect on my daughter. She had been thinking about a career change, and after seeing the impact the nurses at Fox Chase had on their patients, she went back to school and became a nurse.”
— Joan Lautenbacher, lung cancer survivor
CLINICAL

• CAR T-CELL THERAPY
• REMEMBERING GERALD E. HANKS
• LUTATHERA: A NEW DRUG FOR NEUROENDOCRINE TUMORS
• WELCOMING MARIUSZ A. WASIK
• AMBULATORY HEMATOLOGY/ONCOLOGY OFFICE
• PALLIATIVE CARE FELLOWSHIP
• CYSVIEW
• MASTER CLINICIANS
• SURGICAL ONCOLOGY QUALITY INITIATIVES
• WELCOMING NEW PHYSICIANS
CAR T-cell therapy

After passing a rigorous six-month review process, Fox Chase began providing CAR T-cell therapy to eligible leukemia and lymphoma patients. A recently developed intensive form of immunotherapy, CAR T-cell therapy allows doctors to extract and genetically alter T-cells from a patient’s blood, then re-infuse them into the patient. The modified cells are programmed to target and eliminate cancer cells. This approach has shown great promise in treating certain blood cancers, with success rates up to 90 percent for some types of disease.

Fox Chase now provides both FDA-approved CAR T-cell drugs: Kymriah (tisagenlecleucel) from Novartis and Yescarta (axicabtagene ciloleucel) from Gilead Scientists, Inc. Kymriah is approved for the treatment of relapsed or treatment-resistant B-cell acute lymphoblastic leukemia in children and adolescents, as well as for adults with relapsed or refractory large B-cell lymphoma. Yescarta is the first CAR T therapy approved for the treatment of adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, such as chemotherapy.

Henry Fung, MD, FACP, FRCPE, director of the Fox Chase-Temple University Hospital Bone Marrow Transplant Program (BMT), leads the institution’s CAR T-cell therapy practice. During the past year, Fung opened four new clinical trials within the BMT for patients with leukemia, Hodgkin’s lymphoma, and non-Hodgkin’s lymphoma.

Fung is a world-renowned expert in bone marrow and stem cell transplantation, and specializes in treating a range of blood cancers. Under his leadership, the BMT performs more than 100 transplants each year.

Remembering Gerald E. Hanks

Gerald E. Hanks, MD, a giant in the world of radiation oncology and longtime member of the Fox Chase community, died on December 20, 2017 at the age of 83. Hanks served as chair of the Department of Radiation Oncology at Fox Chase for 16 years, retiring in 2001. He is credited with establishing the department’s national prominence. After he retired, he was honored by Fox Chase with the
“CAR T therapy has the potential to greatly improve and extend lives. We are proud that Fox Chase is among a select number of hospitals in the United States approved to administer these therapies.”
— Henry Fung, MD, FACP, FRCPE, director of the Fox Chase-Temple University Hospital Bone Marrow Transplant Program

The creation of the Gerald E. Hanks Chair in Radiation Oncology, which is held by Eric M. Horwitz, MD, FABS, FASTRO, the current chair of the Department of Radiation Oncology. A symposium honoring Hanks’ life and legacy was held March 22, 2018 at Fox Chase, with several renowned radiation oncologists from across the country delivering tributes.

**Lutathera: A New Drug for Neuroendocrine Tumors**

Patients with neuroendocrine tumors got a new treatment option at Fox Chase this year in Lutathera. Neuroendocrine tumors are among the most difficult tumors to diagnose. They can develop anywhere in the body, behave differently based on where they grow, and patients with these tumors often exhibit symptoms that are similar to many other diseases.

Lutathera works by carrying a
Welcoming Mariusz A. Wasik

A significant addition to the Center’s leadership team, Mariusz A. Wasik, MD, joined Fox Chase as chair of the Department of Pathology as well as Associate Director of the Cancer Center. His research focuses primarily on aberrant cell signaling, the underlying genetic and epigenetic mechanisms in lymphomas, the development of new diagnostic and monitoring tools, and the identification of novel treatment approaches based on the unique biology of malignant cells. In addition to continuing this research, Wasik will play a prominent role in supporting Temple University Health System’s cancer service line and strengthening the portfolio of molecular diagnostics and genomic testing within Fox Chase. He is slated to be installed as the Stanley and Stella Bayster Chair in Molecular Diagnostics.

Mariusz A. Wasik, MD, Chair of the Department of Pathology
radioactive component that binds to somatostatin receptors on the tumors and slowly destroys neuroendocrine tumor cells from within, leaving healthy cells unharmed. Clinical trials at Fox Chase and elsewhere have found that Lutathera is an effective treatment for these elusive tumors. For Pam, a Fox Chase patient who had neuroendocrine tumors surgically removed from her small bowel and breast, Lutathera has led to a 15 to 20 percent reduction in the lesions on her liver and lymph nodes. "This is truly a personalized treatment developed specifically for patients who have the somatostatin receptor markers," said Paul F. Engstrom, MD, FACP, a medical oncologist and national leader in the treatment of neuroendocrine tumors. "A large percentage of patients with extensive disease and large differentiated tumors may qualify for this new treatment, which has been a huge advancement."

Fox Chase has long been a leader in the treatment of neuroendocrine tumors. The Center was the first hospital in the greater Philadelphia region to offer the Gallium-68 dotatate PET/CT imaging scan that takes much less time than routine nuclear medicine imaging and exposes the patient to less radiation.

**Ambulatory Hematology/Oncology Office**
The Fox Chase Cancer Center Ambulatory Hematology/Oncology Office

“The amazing thing about Fox Chase is the people. It wasn’t just one person, but a whole team of people, who helped save my life and gave me the best care possible.”
— Preston Moyer, mesothelioma survivor

“Everyone at Fox Chase, from the doctors and nurses to the support staff, made me feel comfortable and welcome at a time when I felt most vulnerable. They care about their patients above all else and it truly shows.”
— Barry Taitelman, kidney cancer survivor
opened in January in the Physicians’ Office Building at Jeanes Hospital. This collaboration provides outpatient cancer care in a convenient space.

The new office specializes in treating patients with benign and malignant blood disorders, such as leukemia, lymphoma, clotting problems, and anemia, as well as solid tumors, such as lung, breast, prostate, and sarcoma. Patients who are treated in this office have the same access to clinical trials and novel treatments as all Fox Chase patients.

Rashmi Khanal, MD, section chief for hematology/oncology at Jeanes Hospital, leads the practice. Vijaykumar Gandhi, MD, an attending physician at Jeanes, helps support this clinic. Several Fox Chase hematologists and oncologists treat and evaluate patients here.

Palliative Care Fellowship
The Pain and Palliative Care Program recruited Stephanie Zankman, DO, to Fox Chase as the first hospice and palliative medicine fellow. The one-year program trains leaders and clinicians in the care of patients with serious illnesses by building skill sets that include expertise in pain and symptom management, communication, complex psychosocial care, and end-of-life care. Molly Collins, MD, director of medical education for the Pain and Palliative Care Program, directs the fellowship. The program supports one fellow each year and includes rotations at Fox Chase, the Hospice of the Visiting Nurse Association of Greater Philadelphia, and Temple University Hospital.

Cysview
This year Fox Chase began offering Blue Light Cystoscopy with Cysview, a revolutionary diagnostic and treatment approach designed to improve detection and removal of early stage bladder cancer with greater accuracy and to reduce recurrence.

When symptoms and blood tests suggest that an individual may have bladder cancer, doctors do a visual inspection of the interior wall of the bladder using a cystoscope — a thin tube with a light and video camera on the end — in a procedure called a cystoscopy.

While larger non-muscle invasive bladder cancer tumors may be visible using white light, smaller cancerous areas may not be easily detected.
“After five rounds of radiation, scans showed that not only had the bleeding stopped, but the tumor was completely gone and the other tumors had shrunk in half. In three months, my health had completely changed.”
— Mahmood Saeed, kidney cancer survivor

because their color can look the same as surrounding healthy tissue.

In the new approach, doctors use a cystoscope equipped with both white and blue light and administer an optical-imaging drug called Cysview that is absorbed by cancer cells. When viewed under the blue light, early stage tumors and lesions glow pink against the healthy tissue, which shows up blue.

Research shows that this approach significantly reduces the chances of recurrence, because it allows surgeons to perform a more complete removal of the cancer. Fox Chase is among a select number of institutions around the country to offer this approach.

Master Clinicians
Richard Greenberg, MD, FACS, professor of urology and urologic surgery, and Elin Sigurdson, MD, PhD, FACS, FRCS (C), professor of general surgery, earned the designation of master clinician this year. The distinction is granted to physicians who have displayed sustained excellence in patient
Under the leadership of chair Robert G. Uzzo, MD, FACS, the Department of Surgical Oncology launched several initiatives in 2018 aimed at improving the quality and safety of patient care, and the efficiency of the operating rooms. The American College of Surgeons National Surgical Quality Improvement Program designated Fox Chase as a meritoriously performing hospital on its All Cases and High Risks lists.

New initiatives this year include Enhanced Recovery After Surgery, an approach designed to help improve recovery from surgery; an ongoing Perioperative Risk Study that studies methods that aim to further reduce the risk of death and serious complications after major cancer surgery; and Swipe-Sense, a technology that increases hand hygiene awareness among anyone who may have direct contact with patients.
Dr. Richard Greenberg performed a radical cystoprostatectomy and urostomy that saved my life. I had many physical changes to cope with, and Dr. Greenberg was in constant contact with my wife and me. He not only preserved my life, but supported me after surgery to adapt to my new lifestyle. He showed a concern not often seen in a surgeon."

— Paul Cervone, bladder cancer survivor

Care, educational instruction, and cutting-edge research at Fox Chase for more than 15 years. Greenberg and Sigurdson will serve as advisors for their respective department chairs, mentor junior faculty, and promote Fox Chase locally and nationally. Sigurdson will mentor faculty on achieving academic success, including publishing papers and research design, while Greenberg will mentor faculty on how to better promote the Fox Chase brand and engage in philanthropy.

Welcoming New Physicians
This year Fox Chase welcomed 23 new clinicians to the faculty in a variety of roles. The Department of Hematology/Oncology added Carlyn Tan, MD, who also completed a fellowship at Fox Chase, Rashmi Khanal, MD, who leads the Hematology/Oncology Program at Jeanes Hospital, board-certified oncologist Emmanuel T. Quien, MD, who treats patients at the Temple Health Northeastern Ambulatory Care campus, board-certified medical oncologist Jason A. Incorvati, MD, who treats patients primarily at Fox Chase East Norriton, Rishi Jain, MD,
MS, DABOM, and Pooja Ghatalia, MD, who also completed a fellowship at Fox Chase. The Department of Surgical Oncology added physician-researcher Shreyas S. Joshi, MD, who also completed a urologic oncology fellowship at Fox Chase and the Department of Radiation Oncology welcomed Sameera Kumar, MD, Randi Cohen, MD, MS, who primarily treats patients at Fox Chase Cancer Center East Norriton, and Sangeeta K. Tyerech, MD, who primarily treats patients at the UHS Prostate Treatment Center.

The Department of Diagnostic Imaging added board-certified radiologist Laura Levin, MD, Meghan Boros, MD, and Andrea M. Abbott, MD. The Department of Medicine welcomed dermatologist Abishek Aphale, MD, hospitalist Hayley E. Walker, MD, interventional gastroenterologist Jennifer Tome Higa, MD, and Julio Noriega, MD, a pulmonologist. Kristen Whitaker, MD, a specialist in breast cancer genetics and prevention, joined the Department of Clinical Genetics.

The Department of Pathology welcomed hematopathologist Reza Nejati, MD, physician-researcher Y. Lynn Wang, MD, PhD, FCAP, and named Mariusz A. Wasik, MD, the new chair of the department and associate director of the cancer center. *
“The level of teamwork and communication amongst the doctors was reassuring. Even though I felt overwhelmed by my multiple surgeries, treatments, and diagnoses, I took immense comfort in the prompt actions taken by my team of physicians.”
— Thomas Myers, melanoma and prostate cancer survivor

“The clinical trial I’m in gave me my life back. With everything I had to worry about, I never second-guessed that I was in the place that was giving me the best options to survive. Once I came to Fox Chase, I knew I was where I need to be.”
— Susie Barton, lung cancer survivor
RESEARCH

- PLIMACK RECEIVES STAND UP TO CANCER GRANT
- THE MARVIN & CONCETTA GREENBERG PANCREATIC CANCER INSTITUTE UPDATE
- PARTNERSHIP WITH UNIVERSITY OF DELAWARE
- WELCOMING PAUL M. CAMPBELL
Elizabeth Plimack, MD, MS, chief of the Division of Genitourinary Medical Oncology at Fox Chase, was awarded a $2.9 million Stand Up To Cancer Catalyst Research Grant to investigate whether the drug guadecitabine can reverse the resistance of some bladder cancers to immunotherapy checkpoint inhibitors. Plimack will work with Peter Jones, PhD, chief scientific officer of Van Andel Research Institute.

While immunotherapy has shown great success in some patients, others have not had the same response. Patients whose tumors grow despite immunotherapy may have parts of their DNA silenced, meaning antigens cannot be expressed to start the tumor rejection process. Guadecitabine can potentially remove this silencing, allowing checkpoint inhibitor immunotherapy to work effectively.
The Marvin & Concetta Greenberg Pancreatic Cancer Institute Update

The Marvin and Concetta Greenberg Pancreatic Cancer Institute, made possible through a transformational gift from Philadelphia philanthropist Concetta Greenberg, has grown impressively since its September 2017 inception. Greenberg’s multi-million-dollar commitment – the largest single gift in Fox Chase history – has elevated the Center’s work in pancreatic cancer research and treatment.

Under co-leaders Igor Astsaturov, MD, PhD, and Edna Cukierman, PhD, the Institute made great strides in its first full year, earning multiple grants and adding key members to the team. In addition to full time researcher

“I would not be able to do as good a job taking care of my patients if I were not also involved in the science and clinical trials. Similarly, I cannot do the science as well without understanding the needs of my patients.”

— Elizabeth Plimack, MD, MS chief of the Division of Genitourinary Medical Oncology
Paul Campbell, PhD, postdoctoral fellow Charline Ogier, PhD, was named the Greenberg Fellow for 2018-19. Kristen Sorice, a project manager who specializes in behavioral science, also joined the Institute to work on the multi-phase development of a Pancreatic Cancer Research Database. The purpose of this database will be to expedite and improve data sharing for multidisciplinary collaborative grants and projects across the center.

**Partnership with University of Delaware**

The University of Delaware has partnered with Fox Chase for the second year in a row to provide UD students with hands-on science and research experience. In line with the educational mission of the Center, the summer program paired Fox Chase research mentors with undergraduate students. The fellows – Deeanne Almeida, Elizabeth Habash, Yasmin Mann, and Carissa Walkosak – received training on how to analyze and present the results of their research and attended a series of talks about careers from guest speakers, including a genetic counselor and a surgeon. To help foster a sense of community, the four students lived together in a house near the Center. The program was supported by the university, Fox Chase, and Thomas Hofmann, a member of the Fox Chase Board of Directors and alumnus of UD.

“As an NCI-designated Comprehensive Cancer Center, it is our duty to train the next generation of engaged, science-literate, health care consumers, and encourage individuals to get involved in the enterprise of discovery.”

— Amanda K. Purdy, PhD, director of academic affairs
Welcoming Paul M. Campbell

Award-winning pancreatic cancer researcher Paul M. Campbell, PhD, joined Fox Chase’s Cancer Biology Program in February. He has earned multiple clinical and translational grants and awards for his work on cancer signaling, progression, and metastasis. Previously he led a lab that studied tumorigenesis driven by the activation of the protooncogene K-Ras. At Fox Chase, Campbell has continued his research focus in these areas, with the overall objective of discovering and validating new targets for drug development and finding novel biomarkers for earlier detection and therapeutic monitoring.

Campbell is an assistant professor, and a member of The Marvin and Concetta Greenberg Pancreatic Cancer Institute at Fox Chase. He holds multiple patents related to cancer therapeutics.
PHILANTHROPY

• ALAN HABER - A SURPRISE GIFT
• IN VINO VITA
• THE LAUREL SOCIETY
• PILOT FUNDING
• NEW HEIGHTS FOR BOARD OF ASSOCIATES
• THE JOY OF GIVING BACK
Alan D. Haber - A Surprise Gift

Alan D. Haber, MD, FCCP, chief of pulmonary, sleep, and critical care medicine at Fox Chase, made the Special Pledge at this year’s *In Vino Vita* Benefit and Wine Auction especially memorable. Sharing lessons from his father and late mother – both of whom survived the Holocaust and later faced cancer – Haber made a $125,000 donation in their honor. Haber spoke about his parents’ lives, lessons, and the spirit of generosity they exemplified. When his father learned about the donation, he matched it, bringing the total gift to $250,000.

Their donation helped make Fox Chase one of the first in the country to offer Auris Health’s Monarch™ Platform, a robotic navigational bronchoscopy system that enables earlier diagnosis and treatment of lung cancer.
In Vino Vita
On April 21, 2018, more than 550 guests gathered for an extraordinary evening in Philadelphia for Fox Chase’s fifth annual In Vino Vita Benefit and Wine Auction, which has evolved into a premier wine event in the region. Through the overwhelming generosity of donors and sponsors – many of whom are faculty, staff, and board members – Fox Chase raised $1.7 million. It was an inspirational evening that brought together like-minded individuals who support the institution’s mission to prevail over cancer.

The highlight of the evening was the special pledge, when guests paused to watch a powerful video in which patients and clinicians highlighted the importance of revolutionizing the delivery of cancer care at Fox Chase. Guests then enthusiastically raised their paddles to pledge their support of the appeal.

Bill and Sue Federici served as this year’s event chairs and championed the Center’s efforts with an offer to match $250,000 toward the special pledge. Louis and Carol Della Penna served as wine chairs and also offered generous support of the event.

The Fox Chase community is already looking forward to next year’s In Vino Vita, which is scheduled for April 6, 2019.

The Laurel Society
The Laurel Society, the premier donor society that honors Fox Chase’s most generous supporters, celebrated its 10th anniversary in 2018. Members of the society gathered in the fall at the Down Town Club in historic Old City Philadelphia for the annual Laurel Society recognition dinner. David Marshall received the Laurel Society Award for his service to Fox Chase, which includes 24 years on the Board of Directors. Fox Chase survivor Karen Cerrato shared her 20-plus year journey with head and neck cancer.

“When you get a second chance at life you make it count, and you pay the gifts you receive in life forward.”
— Alan Haber, MD, FCCP, chief of pulmonary, sleep, and critical care medicine
Pilot Funding

Pilot funding is essential for cancer researchers. It supports cutting-edge projects that offer the potential to extend science in new directions, and does so at a point where it may enable scientists to gather preliminary data needed to secure larger grants. In 2017 Fox Chase began a program to support early-stage researchers with pilot grants. The first five awards were announced in January 2018.

Donors who supported the special pledge at the 2017 *In Vino Vita*, the institution’s signature fundraising event, contributed funding to 10 projects over a two-year period.

The internal review committee evaluated 44 submissions. Effective pilot funding focuses on projects that are potentially paradigm-shifting; possess a high likelihood to lead to significant peer-reviewed funding; address the needs of the community Fox Chase serves; and/or translate laboratory findings into new clinical treatments.

The initial five grants provide funding of $75,000 per year. Two awards were reserved for junior faculty. The following faculty members earned grants in the first round:

- **Sergei Grivennikov, PhD**, for his proposal, “Tumor adherent microbiota as a driver of tumor elicited inflammation in colorectal cancer”
- **Neil Johnson, PhD**, for his proposal, “Targeting the ubiquitin-regulated DNA damage response in BRCA1 mutant cancers”
- **Richard Pomerantz, PhD**, for his proposal, “Discovery of a Novel Reverse Transcriptase in Human Cells: Polymerase ε”
- **Vasily Studitsky, PhD**, and **Italo Tempera, PhD** for their proposal, “Mechanisms of PARP1 action in transcription”
- **Kuang-Yi Wen, PhD**, for her proposal, “To reduce cancer disparities: Mobile TXT to improve hormone therapy adherence in African American BCa survivors”

A second competition for five additional awards began in the fall of 2018.
“Funding for projects is highly competitive, and it can be difficult for junior faculty members to get their research off the ground. Private funding from generous donors can make all the difference in getting great ideas heard and helping junior faculty establish themselves.”
— Jonathan Chernoff, MD, PhD, senior vice president and chief scientific officer

New Heights for Board of Associates
The Board of Associates, a group of dedicated volunteers who raise money year-round through projects and special events in support of research and patient care at Fox Chase, held several events throughout the year.

Founded in 1965, the Board is made up of several member organizations and affiliates, harnessing the passion, creativity, and generosity of more than 500 volunteers who have raised more than $22 million in support of Fox Chase. In 2018, the Young Professionals Chapter was established to offer individuals the unique opportunity to build relationships with fellow advocates ages 21 to 40 through participation in educational, networking, and philanthropic activities.

The Board also held the 18th Annual Paws for the Cause – a one-mile walk
around the Fox Chase campus – on October 22, 2017. FOX29 television anchor Dawn Timmeney and her dog Finley returned for a fifth year to emcee the event, while Richard Greenberg, MD, FACS, who has spent his entire 35-year surgical career at Fox Chase, served as Ambassador along with his dog Cooper. To date, Paws for the Cause has raised more than $400,000.

The Joy of Giving Back
In the 1960s, Evalind “Evie” Minor was a nurse, but her shifts were irregular. As a young mother facing a divorce, she needed a more consistent schedule to raise her daughter. She successfully transitioned to a corporate job, and in 1981 she founded EMSCO Scientific Enterprises, Inc.

Evie is a three-time cancer survivor.

She was treated for ovarian cancer in 2005, kidney cancer in 2010, and bladder cancer in 2015. Thankfully, each cancer was diagnosed at its earliest, most treatable stage, and she had a good outcome. Many of her doctors trained at Fox Chase Cancer Center, and although she was treated at other hospitals, she appreciates what Fox Chase has meant for her.

In 2015, Evie sold her share of the business to retire and spend time with her daughter, son-in-law, and granddaughter. She decided to support Fox Chase with a cash gift in 2018, and is looking forward to seeing the effect of her giving. She also revised her will to include Fox Chase and other institutions close to her heart, in order to leave a lasting impact. By including Fox Chase in her estate plan, Evie became a member of the Elizabeth Anderson Society – Fox Chase’s planned giving society. Gifts like Evie’s help sustain cancer science and medicine well into the future.
“It really takes a special person to work at Fox Chase. Everyone I met had a smile on their face and was incredibly positive. As a receptionist myself, I know it can be a struggle to stay positive all day long. It’s hard to make cancer a positive experience, but I never left feeling discouraged.”
— Tracy Gatto, breast cancer survivor and Paws for the Cause top fundraiser

“Philanthropy is very personal for me. Having lost family members and a close friend to melanoma, I had to get involved with the cause. I’m proud to support Fox Chase, whose care and commitment to patients is inspiring.”
— Neil F. Hall, melanoma survivor and donor
DONORS

The Laurel Society

The Laurel Society is the signature donor society of Fox Chase Cancer Center, honoring the most generous supporters — individuals, corporations, foundations, community fundraisers, and Fox Chase faculty and staff. Individual members demonstrate their commitment by providing annual support of $1,000 or more during Fox Chase’s fiscal year (July 1 through June 30). Corporations, foundations and community fundraisers become members at the $5,000+ level.

Founders’ Circle

$500,000 +

Anonymous
Kendra B. Eager
Concetta Greenberg
Roberta & Ernest Scheller Jr.
The Estate of Eugene Toll

Champions’ Circle

$10,000 - $24,999

Anonymous
Sharon & William J. Avery
The Estate of Alice G. Bassett
Michael Bienvenido
Cindy & Jack Bienvenido
Lucy S. Binder
Suzanne H. & Frank G. Binswanger Jr.
Murray I. Blackman
Joyce F. & Robert L. Byers
Therese M. Carter
Reina S. & Michael A. Cohen
The Estate of Joan M. & John A. Dietze
Carol & Michael D. Ellis
Mary R. & Joseph Faulkner
Amy E. & Leonard F. Feldman
Joseph A. Frick
Catherine R. Getchell
Doris & Arnold Glaberson
Beverly T. & Stephen M. Godshall
Rachel & Eric M. Green

Adèle & Joseph Gugliotta
Bonnie A. & Allen C. Haldeman
Lisa Kabnick & John McFadden
Alice G. & Peter M. Kreindler
Patricia & Eric J. Kropf
Mary K. & Theodore R. Kulp
Jane M. & Kenneth B. Laffend
Jeane Leinen
Naomi P. & Philip E. Lippincott
Wendy H. & Solomon C. Luo
Thomas Manion
Salii & Stephen R. Mickelberg
The Estate of Mary A. Morelli
Leon O. Moulder
Lee & Paul O’Hagan
Sophia O’Hagan
The Estate of Lydia R. Oliver
Doreen H. Paynton
Judith & Anthony Persichilli
Robert W. Pettinato
Ellen Rinaldi & Jeffrey B. Sameroff
Mary D. & Edward J. Roach
Patricia B. & Harris A. Schwartz
Mary Ann Sells & Jonathan Chernoff
Edward Shapiro
Nancy & Benjamin Shein
Ellen L. Sherk
Debra & Leo M. Sniger
Marjorie Stanek
Debra & Leo M. Sniger
Ellen Rinaldi & Jeffrey B. Sameroff
Mary D. & Edward J. Roach
Patricia B. & Harris A. Schwartz
Mary Ann Sells & Jonathan Chernoff
Edward Shapiro
Nancy & Benjamin Shein
Ellen L. Sherk
Debra & Leo M. Sniger
Marjorie Stanek
Debra & Leo M. Sniger
Ellen Rinaldi & Jeffrey B. Sameroff
Mary D. & Edward J. Roach
Patricia B. & Harris A. Schwartz
Mary Ann Sells & Jonathan Chernoff
Edward Shapiro
Nancy & Benjamin Shein
Ellen L. Sherk
Debra & Leo M. Sniger
Marjorie Stanek
Debra & Leo M. Sniger
Ellen Rinaldi & Jeffrey B. Sameroff
Mary D. & Edward J. Roach
Patricia B. & Harris A. Schwartz
Mary Ann Sells & Jonathan Chernoff
Edward Shapiro
Nancy & Benjamin Shein
Ellen L. Sherk
Debra & Leo M. Sniger
Marjorie Stanek

Guardians’ Circle

$5,000 - $9,999

Anonymous
Myra J. & Boyd Asplundh
Myra & John M. Ballinger Jr.
The Estate of Jose E. Barcega
Judith K. & Arnold M. Bernstein
Claire G. & Bernard A. Borghesi
Regina & Robert J. Brennan
The Estate of Edith Brenner
Delbert E. Broughton Jr.
Lizbeth A. & Ed Brunswick
Pamela & Robert L. Byers
Rose & Michael Carbonara
Christine M. Cardamone & William Dauksys
Frances & James Cardea
Karen A. & Jay B. Comly
Denise C. Connolly & Ronald L. Wolf
Judy & Douglas E. Cook
Palma & John M. Daly
Rose Marie A. Deffenbach & John McGinley
Christine & Louis E. Delia Penna Jr.
Linda & Robert Devlin
Lillian & Michael C. DiPiazza
Denise M. & Timothy J. Donahue
Susan C. & William M. Doran
Cheryl S. Edwards
Evelyn & Wafik S. El-Deiry
Elaine T. Emrick
Lori Emrick & Todd J. Glassman
Richard F. Engel
Deborah Flint
Karen A. & Michael D. Flynn
Joan E. & Michael J. Foley
Diane C. & Cameron H. Fowler
Mark B. Fox
Jean A. & G. Wesley Frazier
David Fusco
Barbara R. & Alfonse Gabriele
Arianna Garcia
Peter Giannitacco
Richard E. Greenberg
Jennifer & Christopher Hageman
Diane T. & Robert J. Hansberry
Lynn & Brian Hochberg
Alice M. Hungerford
Barbara T. & Kevin Ilson
Anne E. & John Jadwin
Kevin Kane
Lisa Kimbro & Ray Lynch
Georgia B. & Richard Koenig
Jessica M. Kowalchik
Cynthia & Warren Kruger
Connie & Quintin Lai
Richard F. Lamb
William H. Lambert
The Estate of Amy Lowenstein
Ginny Martin
Susan E. & James McGoldrick
Michael Meister
Roseanne Mistretta

36  FOX CHASE CANCER CENTER  |  PREVAIL  |  ANNUAL REPORT 2018
DONORS

Julia Goplerud & William R. Goldman
Susan Gleckner
Phyllis S. Gitlin
Mary Gerngross
Ursula M. Gentnner
Phyllis S. Gitlin
Mary Gerngross
Ursula M. Gentnner
William R. Goldman
Julia Goplerud & Arland T. Hotchkiss Jr.
Donna T. & Lewis F. Gould
Marilou & David Greed
Marianne T. & Donald T. Green
Larry J. Griffin
Nancy L. Grove & Jim Bunderla
Lois Lehman-McKeeman
Gregory G. Lawton
Lynn Lawrence
Stephen La Neve
Thomas G. Kupp
Marian W. & Walter C. Kinzinger
Michael King
James P. Kilkenny
James A. Kilduff
Larry Keller
Barbara & Leslie Kaplan
Larry Kellar
James A. Kilduff
James P. Kilkenney
Michael King
Marian W. & Walter C. Kinzinger
Ellen J. Kleinman
Melissa Kline
Kristin & Brian R. Kozer
Joy W. Kneider
Thomas G. Kupp
Stephen La Neve
Anna Maria Larenz
Lynn Lawrence
Gregory G. Lawton
Lois Lehman-McKeeman
Gail M. & James Lentz
Arnold Levin
Laura & Daniel S. Levin
Sarah J. Levine
Linda R. & Theodore Liebman
Suzanne & Albert J. Link
LaTonya & Arden L. Liverman
Rochelle M. & Charles Lobel
Jerome Lomurno
Chin Tsai Lu
Andrew Maggion
Vincent Maisano
Donna & Dan Malone
Felix Mandato
Kristen J. & Christopher J. Manley
Angelina & Gerald J. Manna
Brande Mark Falzett & Frank Falzett
Jeffrey Markowitz
Lynn Martin Haskin & Donald Haskin
Lainie Martin
Tina Martocello-Gricoski & John J. Gricoski
Matt Massot
James W. Masterson
Christine A. & William McDonnell
Sean McDonnell
Kathryn Shively McKissock & J. Bruce McKissock
Sandy & William J. McMahon
Janet McMaster
Michelle McMaster
Christopher W. McNichol
David R. McShane
Dorothy & John E. Meggitt
Barton N. Milestone
James W. Miller
Pam & David Miller
Suzanne Miller & Isaak Halegoua
Judith & James F. Mitchell III
Kashmira & Ashok Modi
Gordon Morewood
Anselene M. Morris
Sujana Movva
Michael Mynahan
Bridge & Michael D. Mulcahy
Claire & Thomas J. Mulvaney
Christine E. Muscarenzo & Sameer A. Patel
John G. Nalesnik
Patricia S. & Robert S. Nase
Deborah L. & Kirk J. Nemshick
Melanie J. Norris
Amy & Patrick J. O’Brien
Katherine A. Oodorow-Portnoy & Alan Portnoy
Michael C. Oldfield
Ephe A. Oliver
Robert J. Oddyke
Robert J. Orsher
Catherine A. & Michael R. Owens
Heidi & Scot D. Pannepacker
Nicholas Panos
Catherine & Salvatore S. Paone
Rosaleen & Rick Parsons
Aris Pasles
Pradeep R. Patel
Brian J. Patson
Amanda & Kevin Paul
Ruth C. Paul
Doris L. Peck
Patricia A. & Thomas W. Peddie
Ellen R. & Jeffrey W. Plaut
Denise H. & Jeffrey H. Porter
Kathleen & Patrick Poyser
Valerie K. & Robert A. Price
Estelle & Stuart E. Price
David Pru ylock
Amanda K. Purdy & Thomas B. Cook
Kim L. Rainey-Nichols & Scott J. Nichols
Beth Ann F. & Adam Rainier
Jessica & Marc Reider
Julia Resnick Hoffman & John P. Hoffman
Adelina Rigolot
Marthe Ann Roberts-Shea & Thomas J. Shea
Nancy & Brian D. Robinson
Richard C. Roden
Fereshteh & Heinrich Roder
Michelle Rodolz
Janice Romano
Shari & Mark Rosenberg
Jill S. & Norman G. Rosenblum
Stephen Rosenzweig
Pelsen yed Roshanak & Hormoz Ehy
Deborah K. & David E. Ross
Seymore Rubin
Rose A. Ruggiero
Teena & Scott Russell
Zahra & Mahmood Saeed
Joyce S. Sando
Daphne Sawyer
Tina Schechter
Jessie Schol & Sarah Schol
Kathryn & Kenneth A. Schuyler
Marilyn & Alan C. Schwedel
Michelle & Stephen A. Scialdone
Celeste H. Sculthorpe
Thomas Seaman
Josephine C. Sha
Bonne & Donald S. Shanos
Dorothy E. Siebert
Keiko & John R. Simon
Anna Marie & Rudolph Skalka
Susan & Ronald L. Smith
Donna L. & Timothy G. Smith
Lindy Snider & Larry R. Kaiser
Cynthia & Howard S. Solganick
Judith K. & Cecil D. Southard
Elise L. Spiero
Kristin & Kevin Sterling
Zelda R. Stern
Janice A. Stilley
Julie I. Stone & Harry S. Shanis
Beth V. & Vinson P. Stouck
Nancy L. & Raymond J. Svitak
Pauline L. & Michael J. Sweeney
Christine E. Szarka
Stephen B. Tanner
Christine Taylor
Robert R. Taylor
Priscilla L. & Joseph R. Testa
Jacqueline G. & Frederick P. Thomas
Jeffrey L. Tokar
Elizabeth L. & Stephen J. Tolkach
Mary & Augustus J. Tornetta
Dorothy M. & Edward Tosti
Joseph A. Treat
Louise & Thomas R. Tritton
David J. Tsui
Jacob Ulmer
Donald J. Van Alstyne
Julie M. Van Campen
Marcia & William Vanderslice
Nancy Vasta
Elizabeth & John H. Velardi
Beth C. & Joseph J. Villafranca
Mary T. Wairond-Goff
Maryanne Walsh
Derek Walters
Elizabeth R. & David S. Wampler
Yang Wang & Jian Yu
Tricia & David Ware
Janet A. Wassum
Elizabeth & Robert Watts
Miriam & Homer Weaver
Ruth Weber
Nina Weisbord & George Wood
Geoffrey R. Weiss
Stephanie Weiss & Hugh Mclaughlin
Meghan Whitcraft & Sanjay S. Reddy
Robert L. Winfree
Jason N. Wolfe
Roni Wolfson
Marcia A. & Jay Yanoff
Anthony A. Yoseloff
Susan Zucotti

CORPORATIONS, FOUNDATIONS & ORGANIZATIONS

Leaders’ Circle
$20,000+

Fifth District AHEPA Cancer Research Foundation
AstraZeneca Pharmaceuticals
The Benevity Community Impact Fund
Fox Chase Cancer Center - Board of Associates
- Bucks County Chapter
- Dan’s Voice
- Martyn Fein Chapter
- Fox Chase Chapter
- Friends of Fox Chase Cancer Center
- Jimbo’s Squad
- Main Line Chapter
- Carve for Cancer, Inc.
- Christopher M. Fuga Memorial Fund
- Colon Cancer Coalition
- Digital Science Press, Inc.
- Foundation Medicine
- The Fund for Charitable Giving
- Genentech, Inc.
- The Gitlin Family Foundation
- Glassman Family Foundation
- Chris Spratt Foundation, Inc.
- Glycol Sciences, Inc.
- The Harry & Jeanette Weinberg Foundation, Inc.
- Independence Blue Cross
- IRS Sirius Group LLC
- Insitut de Cancerologie de France
- Johnson & Johnson
- Kicking Cancer Foundation
- The Lenore & Howard Klein Foundation
- LAOH Brigid McCrory Division 25
- Left Coast Cellars
- Merck & Company, Inc.
- Mid-Atlantic Packaging, Inc.
- NeoGenomics Laboratories, Inc.
- Network for Good
- New Hope Auto Show
- New Hope-Solebury Community Association
- Norristown Bocce League
- Novartis Pharmaceuticals Corporation
- Old York Road Country Club
- Women’s Golf Association
- Oscar H. & E. Ida Tucker Memorial Fund
- Rita R. Holman Breast Cancer Foundation Inc.
- Kahn Testamentary Foundation
- Robert Wood Johnson Foundation
- Sanofi-Aventis, U.S., Inc.
- Sarcoma Foundation of America, Inc.
- Schultz & Williams
- Stradley, Ronon, Stevens & Young LLP
- Takeda Pharmaceuticals U.S.A., Inc.
- Tanner Industries, Inc.
- Temple University School of Medicine
- TESARO, Incorporated
- Trust
- Ukrainian American Sports Center
- Vertical Bridge REIT, LLC
- Weitz & Luxenburg PC
- White Engineering Surfaces Corporation
- YourCause, LLC Trustee

Elizabeth Anderson Society

The Elizabeth Anderson Society honors thoughtful friends of Fox Chase who have established gifts in the form of a bequest, gift annuity, charitable remainder trust, charitable lead trust, life insurance policy, retirement account, or select gifts of real estate.

Anonymous
Suzanne Balbirer
Toni-Lee Beigel
John C. Bennett
Catherine & Walter G. Bittner
Raphaela Blum
Kay & Mike Breuninger
Kathleen Bullano
Robert C. Busby
Christina M. Canales
Kenneth B. Charlesworth
Margaret A. & Thomas A. Coughlin
Robert J. Cronk
Maureen E. & J. Russell Cullen
Elizabeth Dambrowski
Emily M. Dannaker
Helen R. Davis
Nancy L. Day
Carol A. & Louis E. Delia Penna, Sr.
Linda & Robert Devlin
Arline L. & Ira R. Dolch
Sondra Doner
Kendra B. Eager
Yvonne Eldridge
Carol Elfant
Beth K. Kocher-Ferraro & Frank Ferraro
Louise Penow Flurer
Barbara R. & Alfonso J. Gabriele
Helen J. Gebhardt
Catherine R. Getchell
Nancy E. Goldy
Concetta Greenberg
Elizabeth K. Grenald
Edith D. & Frank M. Highley
Lois Hitchman
Hoffman Family Trust
Jane E. Hollenbach
Alice M. Hungerford
David P. Ineich
Alma R. Jacobs
Nancy & Rodney D. Johnson
Joan E. Jones
Mary Ann Jones
Barbara R. & Charles Kahn Jr.
Gwendolyn S. King
Janet C. Kistner
Janet B. Kovacs

Geraldine M. Kozempel
Martha J. & R. Donald Leedy
Michael Levin
Wendy & Andrew L. Lewis
Naomi & Philip E. Lippincott
Susan & William G. Little
Angela M. Lynch
Nancy Markovich
Richard B. Millham, Sr.
Cathie M. Minehart
Evaluind Minor
Beatrice Mintz
Judith A. & James F. Mitchell III
Diane & David M. Morgan
Michael J. Nauss
Elma Neeld
Diane W. Nyland
John E. Orban III
Kaye Paetz
Sandra L. Paugh
Wenona & Raymond A. Paul
Sally Peirson
Jane G. Pepper
Beatrice C. Pilch
Irina S. Platnick
Clare K. Porac
Joanne & Alexander Rankin
Joseph Rees
Edward J. Roach
Richard C. Roden
Jayne H. & Paul I. Rosen
John Ruggio
Rev. Cecily Sawyer Harmon
Daphne B. Sawyer
Carol Schramek
Karen Schwartz
Josephine Scully
Lia M. Skillern & Theodore S. Dalstrom
Barbara L. Sparks
Zuzanna L. & Roger J. Stankay
Bonnie Stock
Nancy K. Switzer
Norma Tither
Wendy B. Trow-Fox & Remy L. Fox
Adele E. Veilh
Anna Vinerova
Norman F. Watts
Sandra W. & Timothy C. Weckesser
Naomi Weiss
Justin L. Young
Joyce C. Zimmerman

*Deceased

Friends’ Circle

$5,000 - $9,999

20/20 Audio Visual, Incorporated
Abington Friends School
Abraham M. & Rose Ellis Foundation
Adelphi Lodge B’nai B’rith Charities Foundation
AIG Investor Relations
Alpha Theta Alpha
Amen Inc.
The Morris S. & Florence H. Bender Foundation
Boehringer-Ingelheim Pharmaceuticals, Inc.
The Brenda Trust
Bristol-Myers Squibb Company, Worldwide Medicines
Broughton Foundation
Byers Choice, Ltd.
C.W.A. Local 13080
Dr. Don Cardeo Golf Outing
Caris Life Sciences
Celtgene
The Jay Comly Family Bike-a-Thon
A Day in the Park with Tommy Z.
## FINANCIALS

### 2018 BY THE NUMBERS
- 707 Scientific Publications
- 113,546 Outpatient Visits
- 8,652 New Patients
- 23 New Faculty Members

Numbers represent Fiscal Year 2018

### PHILANTHROPY SNAPSHOT
- $14,400,000 Total Philanthropic Support
- $1,700,000 Raised at In Vino Vita
- 10,201 Total Donors
- 2,978 Total New Donors
- 612 Current Donors Who Have Given 30+ Years
- $711,217 Board of Associates Total Gifts

### VOLUNTEER SNAPSHOT
- 524 Volunteers
- 84,741 Total Volunteer Hours
- $269,413 Volunteer Department Budget
- $2,092,255 Value of Hours*
- $1,822,842 Net Value Added to Fox Chase

*Based upon the Independent Sector Value of $24.69/hr.

### ACTIVELY ENROLLING CLINICAL RESEARCH STUDIES
- 302

### INVESTIGATOR INITIATED CLINICAL RESEARCH STUDIES
- 91
## CLINICAL SNAPSHOT (In Thousands)

### REVENUES | CLINICAL ACTIVITY

<table>
<thead>
<tr>
<th>Revenue Source</th>
<th>Hospital</th>
<th>Physicians</th>
<th>Philanthropy, Outreach &amp; Other</th>
<th>Clinical Revenue</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient Care Revenue</td>
<td>$365,219</td>
<td>$35,326</td>
<td>$11,574</td>
<td><strong>$412,119</strong></td>
</tr>
</tbody>
</table>

### OPERATING EXPENSES | CLINICAL ACTIVITY

<table>
<thead>
<tr>
<th>Expense Category</th>
<th>Hospital</th>
<th>Physicians</th>
<th>Administrative &amp; General</th>
<th>Capital Related Costs</th>
<th>Maintenance &amp; Plant Operations</th>
<th>Clinical Expenses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Direct Patient Care</td>
<td>$292,399</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>$371,610</strong></td>
</tr>
<tr>
<td>Support Services</td>
<td></td>
<td>$17,929</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Administrative &amp; General</td>
<td></td>
<td></td>
<td>$40,707</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Capital Related Costs</td>
<td></td>
<td></td>
<td></td>
<td>$9,106</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maintenance &amp; Plant Operations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>$11,469</td>
<td></td>
</tr>
</tbody>
</table>

### KEY PATIENT CARE STATISTICS

- New Patients: 8,652
- Hospital Admissions: 4,304
- Chemotherapy Infusions & Related Procedures: 63,089
- Radiation Therapy Treatments: 26,616
- Surgical Procedures: 4,980

## RESEARCH SNAPSHOT

### ACTIVE FUNDED PROJECTS

<table>
<thead>
<tr>
<th>Funding Source</th>
<th>Number of Projects</th>
<th>Direct Costs</th>
<th>Total Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>PEER-REVIEWED</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCI</td>
<td>100</td>
<td>$13,287,213</td>
<td>$20,906,040</td>
</tr>
<tr>
<td>Other NIH</td>
<td>57</td>
<td>$9,557,749</td>
<td>$15,353,385</td>
</tr>
<tr>
<td>Other</td>
<td>29</td>
<td>$3,440,101</td>
<td>$4,753,121</td>
</tr>
<tr>
<td>Subtotal of peer-reviewed</td>
<td>186</td>
<td>$26,285,063</td>
<td>$41,012,546</td>
</tr>
<tr>
<td>NON PEER-REVIEWED</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Industry</td>
<td>77</td>
<td>$6,434,927</td>
<td>$8,117,822</td>
</tr>
<tr>
<td>Other non peer-reviewed</td>
<td>29</td>
<td>$1,688,323</td>
<td>$1,914,418</td>
</tr>
<tr>
<td>Subtotal of non peer-reviewed</td>
<td>106</td>
<td>$8,123,250</td>
<td>$10,032,240</td>
</tr>
</tbody>
</table>

### GRAND TOTAL

- **$34,408,313**
- **$51,044,786**
FINANCIALS

TYPES OF CANCERS TREATED

- Pancreas: 3%
- Head & Neck: 3%
- Lymphoma: 3%
- Bladder: 5%
- Kidney: 5%
- Skin: 5%
- Colorectal: 6%
- Gynecological: 8%
- Lung: 12%
- Prostate: 15%
- Breast: 19%
- Other: 16%

Numbers represent Fiscal Year 2018.
FY18 PAYER MIX

- COMMERCIAL: 42%
- MEDICARE: 36%
- MEDICARE MANAGED CARE: 13%
- MEDICAID: 8%
- SELF-PAY/OTHER: 1%
LEADERSHIP & FACULTY

Senior Administrators
Richard I. Fisher, MD
President & Chief Executive Officer
Cancer Center Director
Senior Associate Dean, Lewis Katz School of Medicine at Temple University
J. Robert Beck, MD
Senior Vice President
Deputy Director
Chief Administrative Officer
Jonathan Chernoff, MD, PhD
Deputy Director
Chief Scientific Officer
Glenn F. Rall, PhD
Chief Academic Officer
Wafik S. El-Deiry, MD, PhD
Deputy Cancer Center Director for Translational Research
Judith L. Bachman, MSN, RN, CNA
Chief Operating Officer
Ray Lynch, CPA, MBA
Chief Financial Officer
James Helstrom, MD, MBA
Chief Medical Officer
Anne Jadwin, RN, MSN
Chief Nursing Officer
Shawn Kleitz
Chief Development Officer

Fox Chase Cancer Center Foundation Board of Directors
CHAIR: Donald E. Morel, Jr., PhD
VICE CHAIR: Louis E. Bella Penna Sr.
William J. Federici
Richard I. Fisher, MD
Edward A. Glickman
Lewis F. Gould Jr.
Thomas W. Hofmann
Barbara Ilzen
Margot Wallace Keith
Geoffrey Kent
Fran Levin
Philip E. Lippincott
Solomon C. Luo, MD
David G. Marshall
Edward J. Roach
Lindy Snider
Thomas R. Tritton, PhD

Fox Chase Cancer Center Endowed Chairs
LOUIS DELLA PENNA FAMILY CHAIR
Drew Ridge, MD, PhD, FACS
Chief, Head and Neck Surgery

CAROL & LOUIS DELLA PENNA CHAIR
Richard E. Greenberg, MD, FACS
Professor, Department of Surgical Oncology

G. MORRIS DORRANCE JR. CHAIR
in Medical Oncology
Martin J. Edelman, MD
Chair, Department of Hematology/Oncology

MARVIN S. GREENBERG, MD, CHAIR
in Pancreatic Cancer Surgery
John P. Hoffman, MD, FACS
Chief, Pancreaticobiliary Service

PAUL GROTZINGER & WILBUR RAAB CHAIR in Surgical Oncology
Stephen C. Rubin, MD
Chief, Division of Gynecologic Oncology

SAMUEL M.V. HAMILTON CHAIR
in Cancer Prevention
Paul F. Engstrom, MD, FACP
Chief, Section of General Hematology/Oncology

GERALD E. HANKS CHAIR
in Radiation Oncology
Eric M. Horwitz, MD
Chair, Radiation Oncology

G. WILLING “WING” PEPPER CHAIR
in Cancer Research
Robert G. Uzzo, MD, FACS
Chair, Department of Surgical Oncology

STANLEY P. REIMANN CHAIR
in Oncology Research
Jonathan Chernoff, MD, PhD
Chief Scientific Officer

TIMOTHY R. TALBOT JR. CHAIR
in Cancer Research
Mary B. Daly, MD, PhD, FACP
Director, Risk Assessment Program

CAROL & KENNETH WEG CHAIR
in Human Genetics
Joseph R. Testa, PhD, FACP
Co-Leader, Cancer Biology Program

AUDREY WEG SCHAUS & GEOFFREY ALAN WEG CHAIR in Medical Science
David S. Weinberg, MD, MSc
Chair, Department of Medicine

H.O. WEST & J.R. WIKE CHAIR
in Cancer Research
J. Robert Beck, MD
Chief Administrative Officer

ROBERT C. YOUNG, MD, CHAIR
in Cancer Research
Richard I. Fisher, MD
President & Chief Executive Officer

Pending Appointments
THE GLORIA & EDMUND M. DUNN CHAIR in Thoracic Surgical Oncology

THE DONALD E. & SHIRLEY C. MOREL, STANLEY & STELLA BAYSTER CHAIR in Molecular Diagnostics

Clinical Faculty
Department of Clinical Genetics
INTERIM CHAIR: Michael J. Hall, MD, MS
Mary B. Daly, MD, PhD
Elias Obeid, MD, MPH
Kristen Whitaker, MD

Department of Diagnostic Imaging
CHAIR: Rosaleen Parsons, MD
Andrea M. Abbott, MD
Sarah Abdulla, MD
LEADERSHIP & FACULTY

Mark Andrake, PhD
Igor Astsaturov, MD, PhD1
Hossein Borghaei, DO1
Yanis Boumber, MD, PhD
Denise C. Connolly, PhD
Roland L. Dunbrack Jr., PhD
Martin J. Edelman, MD
Brian L. Egleston, PhD
Margret Einerson, PhD
Lori J. Goldstein, MD1
Vasily M. Studitsky, PhD

PRIMARY MEMBERS
Andrew J. Andrews, PhD
Alfonso Bellacosa, MD, PhD
Nora Engel, PhD2
Jian Huang, MD, PhD2
Jaroslav Jelinek, MD, PhD2
Richard A. Katz, PhD
Elizabeth R. Plimack, MD, MS1
Carmen Sapienza, PhD2
Bassel E. Sawaya, PhD2
Italo Tempera, PhD2
Hong Wang, MD, PhD2
Yi Zhang, MD, PhD2

1 Member of the Fox Chase Cancer Center clinical faculty
2 Faculty based at Temple University

Cancer Prevention & Control

PROGRAM LEADERS
Margie L. Clapper, PhD
Carolyn Y. Fang, PhD

PRIMARY MEMBERS
Nezar Al-Hebshi, PhD2
Sanjeevani Arora, PhD
J. Robert Beck, MD
Bradley N. Collins, PhD2
Mary B. Daly, MD, PhD1
Efrat Dotan, MD1
Paul F. Engstrom, MD1
Susan Gross Fisher, PhD2
Ana M. Gamero, PhD2
Daniel Geynisman, MD1
Sergei Grivennikov, PhD
Michael J. Hall, MD1
Enrique Hernandez, MD2
Resa James, MPH, PhD2
Stephanie Lapon, PhD2
Shannon Lynch, PhD, MPH
Grace X. Ma, PhD2
Suzanne M. Miller, PhD
Elias Obeid, MD1
Camille Ratin, PhD
Jennifer Reese, PhD
Laura Siminoff, PhD2
David S. Weinberg, MD1
Kuang-Yi Wen, PhD

Cancer Epigenetics

PROGRAM LEADERS
Jean-Pierre J. Issa, MD2

PRIMARY MEMBERS
Andrew J. Andrews, PhD
Alfonso Bellacosa, MD, PhD
Nora Engel, PhD2
Jian Huang, MD, PhD2
Jaroslav Jelinek, MD, PhD2
Richard A. Katz, PhD
Elizabeth R. Plimack, MD, MS1
Carmen Sapienza, PhD2
Bassel E. Sawaya, PhD2
Italo Tempera, PhD2
Hong Wang, MD, PhD2
Yi Zhang, MD, PhD2

1 Member of the Fox Chase Cancer Center clinical faculty
2 Faculty based at Temple University

The Annual Report is produced by the Communications Department of Fox Chase Cancer Center. Contact us at editor@fccc.edu.

Temple Health refers to the health, education and research activities carried out by the affiliates of Temple University Health System (TUHS) and by The Lewis Katz School Temple University School of Medicine. TUHS neither provides nor controls the provision of health care. All health care is provided by its member organizations or independent health care providers affiliated with TUHS member organizations. Each TUHS member organization is owned and operated pursuant to its governing documents.

Jeremy Moore
Senior Director of Communications

Andrew Becker
Director of External Communications

Paige Allen
Staff Writer

Rachel D’Ascendis
Editorial Assistant

Writers & Contributors
Paige Allen
Rachel D’Ascendis
Jill Horne

Photography
PORTRAITS: Colin Lenton
REPORTAGE: Nina Hein

Design
B&G Design Studios

Printing
Brilliant Graphics
HISTORY

1904
A group of physicians and businessmen signed the charter to establish the American Oncologic Hospital. The hospital opened on January 4, 1905, becoming one of the first hospitals in the country devoted exclusively to treating cancer.

1925
Stanley P. Reimann, MD, chief pathologist at Lankenau Hospital, founded the Lankenau Hospital Research Institute. In 1945 it would evolve into the Institute for Cancer Research.

1959
David A. Hungerford, a doctoral student at the Institute for Cancer Research, and Peter C. Nowell, MD, from the University of Pennsylvania, discovered what would become known as the Philadelphia Chromosome. It was the first conclusive evidence that cancer is a genetic disorder of somatic cells.

1967
Baruch S. Blumberg, MD, PhD, made the world-changing discovery of the hepatitis B virus, a major cause of primary liver cancer, the fifth-most common cancer worldwide. Within two years Blumberg and Irving Millman, PhD, developed a vaccine to prevent the virus. It was the first vaccine that prevents a form of cancer in humans. Blumberg is credited with preventing millions of cases of liver cancer over the ensuing decades. He received the Nobel Prize in Medicine in 1976, and he and Millman were elected to the National Inventors Hall of Fame in 1993.

1974
The American Oncologic Hospital and the Institute for Cancer Research united to form Fox Chase Cancer Center. That same year, Fox Chase became one of the first institutions to earn the National Cancer Institute’s elite designation as a Comprehensive Cancer Center.

1995
Fox Chase became a founding member of the National Comprehensive Cancer Network, an alliance of the nation’s leading academic cancer centers designed to ensure the highest-quality, most cost-effective, cancer care based on state-of-the-art treatment guidelines and outcomes research.

2004
Fox Chase’s Irwin A. Rose, PhD, and collaborators Avram Hershko, MD, PhD, and Aaron Ciechanover, MD, PhD, received the Nobel Prize in Chemistry in recognition of their work together at Fox Chase from the 1970s through the early 1980s. The group discovered one of the cell’s most important cyclical processes: how proteins are broken down and recycled.